SEC EDGAROCT 161 min read$MDT

Martha Geoffrey sold $4.8M of MDT

Martha Geoffrey (Chairman and CEO) sold 50,000 shares of Medtronic plc (MDT) at $95.00 ($4.75M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Martha Geoffrey

Published Oct 16, 2026, 10:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 16, 2026, 10:06 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MDT

Bearish

medium confidence

Mentioned

$MDT

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MDTBearishLow

Why it matters

The disclosed sale adds new information about Medtronic's leadership holdings, which can affect short‑term price dynamics.

Market read

The filing provides fresh data on insider holdings, a factor many traders monitor for potential price moves.

What to watch

Potential tax planning or diversification needs of the insider are not disclosed.

Relevance 5/10Novelty 8/10Timing: after‑hours filing

Background

Form 4 filings are primary disclosures of insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MDTBearishMedium confidence

Context

CEO Martha Geoffrey sold 50,000 Medtronic shares for $95 each, a $4.75M open‑market sale filed on Form 4.

Expected impact

likely slight downward pressure as investors digest the sell‑off

Evidence & confidence

A $4.75M sale by the chairman/CEO is material for a mid‑cap medical device company and often triggers short‑term selling.

Market effects

Sector

May prompt scrutiny of other medical‑device stocks for insider activity.

Regional

Limited to U.S. equities; no broader regional effect.

Global

Minimal; only relevant to investors tracking Medtronic.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

person
Martha Geoffrey
Chairman and CEO of Medtronic plc
company
Medtronic plc
Global medical‑device manufacturer (ticker MDT)

Read at source ← All news

OCT 23

$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

hcplive.com2 min

OCT 23

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

finance.yahoo.com2 min

OCT 22

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min

OCT 22

$MDTMedAI 8/10

Medtronic Reports Positive Real-World Data For Cardiac Ablation Systems

Medtronic (MDT) presented positive real-world data for its cardiac ablation systems at the APHRS 2026 meeting. The Sphere-9 catheter and PulseSelect PFA system showed low complication rates and high success rates in treating heart rhythm disorders. MDT stock closed at $93.03, up 0.25% in pre-market trading.

rttnews.com2 min

OCT 20

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

medicaldevice-network.com2 min

OCT 19

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.